<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002295</url>
  </required_header>
  <id_info>
    <org_study_id>008F</org_study_id>
    <secondary_id>ISO-141-USA</secondary_id>
    <nct_id>NCT00002295</nct_id>
  </id_info>
  <brief_title>A Study of Isoprinosine in Patients With Severe AIDS</brief_title>
  <official_title>A Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Severe Acquired Immunodeficiency Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newport Pharmaceuticals International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to:&#xD;
&#xD;
      Laboratory (immunologic defects):&#xD;
&#xD;
        -  Comparison of total helper and suppressor T-cell numbers among the groups.&#xD;
&#xD;
        -  Comparison of changes in natural killer cell activity.&#xD;
&#xD;
        -  Comparison of other laboratory findings among the groups.&#xD;
&#xD;
      Clinical changes:&#xD;
&#xD;
        -  Comparison of the frequency of opportunistic infections among the groups.&#xD;
&#xD;
        -  Comparison of the frequency of the development of AIDS-related malignancies.&#xD;
&#xD;
        -  Comparison of other clinical manifestations relative to severity and time of onset.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inosine pranobex</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and&#xD;
        severe gastric ulcer are excluded.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Cytotoxic immunosuppressive agents.&#xD;
&#xD;
          -  Radiotherapy.&#xD;
&#xD;
        The following are excluded:&#xD;
&#xD;
          -  Critically ill patients.&#xD;
&#xD;
          -  Patients receiving steroids, cytotoxic immunosuppressive agents, radiotherapy.&#xD;
&#xD;
          -  Patients who have received any other immunotherapy.&#xD;
&#xD;
          -  Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and&#xD;
             severe gastric ulcer.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any other immunotherapy.&#xD;
&#xD;
        Patients with severe AIDS and specified laboratory immunologic defects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Newport Pharmaceuticals International Inc</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92656</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Infusions, Intravenous</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Biological Availability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inosine Pranobex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

